Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Abstract

Pre-exposure prophylaxis (PrEP) involving daily tenofovir disoproxil fumarate/emtricitabine 300/200 mg, taken orally, is a highly effective strategy for reducing the risk of HIV acquisition in adults who are at high, ongoing risk of infection.